Pharmacogenetics may influence tacrolimus daily dose, but not urinary tubular damage markers in the long-term period after renal transplantation

Background: The primary goal of this study was to evaluate the influence of cytochrome P450 (CYP) 3A5 (6986A>G) and ABCB1 (3435C>T) polymorphisms on tacrolimus (TAC) dosage regimen and exposure. Second, we evaluated the influence of TAC dosage regimen and the tested polymorphisms on renal oxid...

Full description

Bibliographic Details
Published in:	Journal of Medical Biochemistry
Main Authors:	Stefanović Nikola Z., Cvetković Tatjana P., Veličković-Radovanović Radmila M., Jevtović-Stoimenov Tatjana M., Vlahović Predrag M., Stojanović Ivana R., Pavlović Dušica D.
Format:	Article
Language:	English
Published:	Society of Medical Biochemists of Serbia, Belgrade 2015-01-01
Subjects:	abcb1 cyp3a5 oxidative stress renal transplantation tacrolimus tubular damage
Online Access:	https://scindeks-clanci.ceon.rs/data/pdf/1452-8258/2015/1452-82581504422S.pdf

Similar Items

Effect of the Interrelation between CYP3A5 Genotype, Concentration/Dose Ratio and Intrapatient Variability of Tacrolimus on Kidney Graft Function: Monte Carlo Simulation Approach
by: Nikola Stefanović, et al.
Published: (2021-11-01)

Progress in pharmacogenetic studies on effect on tacrolimus concentrations
by: YANG Shuang, et al.
Published: (2020-01-01)

Effect of ABCB1 (3435C>T) and CYP3A5 (6986A>G) genes polymorphism on tacrolimus concentrations and dosage requirements in liver transplant patients
by: Marwa Helal, et al.
Published: (2017-07-01)

The Impact of CYP3A4*22 on Tacrolimus Pharmacokinetics and Outcome in Clinical Practice at a Single Kidney Transplant Center
by: Emaad Abdel-Kahaar, et al.
Published: (2019-09-01)

<i>CYP3A5*3</i> and <i>CYP3A4*22</i> Cluster Polymorphism Effects on LCP-Tac Tacrolimus Exposure: Population Pharmacokinetic Approach
by: Zeyar Mohammed Ali, et al.
Published: (2023-11-01)

Influence of different formulations of tacrolimus on dosage regimen and drug exposure within the first year after kidney transplantation
by: Stefanović Nikola Z., et al.
Published: (2019-01-01)

Refining tacrolimus dosing through CYP3A5 pharmacogenetics in Taiwanese renal transplant recipients
by: Yen-Lin Chang, et al.
Published: (2025-12-01)

CLOPIDOGREL PHARMACOGENETICS
by: A. N. Meshkov
Published: (2016-01-01)

Insights into the Pharmacogenetics of Tacrolimus Pharmacokinetics and Pharmacodynamics
by: Mercè Brunet, et al.
Published: (2022-08-01)

Drug-drug interactions of tacrolimus
by: Rančić Nemanja K., et al.
Published: (2015-01-01)

Pharmacogenetic studies in Alzheimer disease
by: T. Zúñiga Santamaría, et al.
Published: (2022-05-01)

Analysis of Tacrolimus Clearance in Patients with Kidney Transplants from Romania
by: Corina Andreea Rotarescu, et al.
Published: (2025-06-01)

Pharmacogenetics Approach for the Improvement of COVID-19 Treatment
by: Ingrid Fricke-Galindo, et al.
Published: (2021-03-01)

Pharmacokinetics and Pharmacogenetics of Apixaban
by: A. V. Savinova, et al.
Published: (2020-11-01)

Frequency of CYP3A5 Genetic Polymorphisms and Tacrolimus Pharmacokinetics in Pediatric Liver Transplantation
by: Jefferson Antonio Buendía, et al.
Published: (2020-09-01)

Beyond Single Nucleotide Polymorphisms: CYP3A5∗3∗6∗7 Composite and ABCB1 Haplotype Associations to Tacrolimus Pharmacokinetics in Black and White Renal Transplant Recipients
by: Daniel A. Brazeau, et al.
Published: (2020-08-01)

Induction of CYP3A activity by dexamethasone may not be strong, even at high doses: insights from a case of tacrolimus co-administration
by: Yoshiyuki Ohno, et al.
Published: (2023-12-01)

Clinical and safety outcomes of conversion original tacrolimus to generic tacrolimus in Turkish kidney transplant recipients
by: Emrah Günay
Published: (2020-09-01)

Pharmacogenomic Analysis of CYP3A5&ast;3 and Tacrolimus Trough Concentrations in Vietnamese Renal Transplant Outcomes
by: Nguyen TVA, et al.
Published: (2024-02-01)

CYP3A5 polymorphisms in renal transplant recipients: influence on tacrolimus treatment
by: Chen L, et al.
Published: (2018-03-01)

Effect of CYP3 A4, CYP3 A5 and ABCB1 gene polymorphisms on the clinical efficacy of tacrolimus in the treatment of nephrotic syndrome
by: Min Li, et al.
Published: (2018-04-01)

Tacrolimus—why pharmacokinetics matter in the clinic
by: Lino Henkel, et al.
Published: (2023-08-01)

Impact of CYP3A4 and CYP3A5 polymorphisms on tacrolimus dose requirements in Saudi kidney transplant patients
by: Marzog S. Al Nasser, et al.
Published: (2025-08-01)

Systematic Review of Pharmacogenetics of Immunosuppressants in Heart Transplantation
by: Juan Eduardo Megías-Vericat, et al.
Published: (2025-06-01)

Donor and recipient genetic variants in drug metabolizing enzymes and transporters affect early tacrolimus pharmacokinetics after liver transplantation
by: Alexandra D. Ladd, et al.
Published: (2025-07-01)

Impact of combined CYP3A4 and CYP3A5 single- nucleotide polymorphisms on tacrolimus exposure and acute rejection in Egyptian pediatric kidney transplant recipients: single center experience
by: Fatina I. Fadel, et al.
Published: (2025-09-01)

The distribution of genetic polymorphism of CYP3A5, CYP3A4 and ABCB1 in patients subjected to renal transplantation
by: Vavić Neven, et al.
Published: (2016-01-01)

Effects of CYP3A5 Polymorphisms on Efficacy and Safety of Tacrolimus Therapy in Patients with Idiopathic Membranous Nephropathy
by: Zhang C, et al.
Published: (2020-04-01)

The Impact of Single Nucleotide Polymorphisms on the Pharmacokinetics of Tacrolimus in Kidney Allograft Recipients of Northern-West, Iran
by: Elaheh Jabbari Hagh, et al.
Published: (2023-03-01)

Case report and literature review: management of Paxlovid (nirmatrelvir/ritonavir)-induced acute tacrolimus toxicity in a patient with systemic lupus erythematosus
by: Chenxiao Jiang, et al.
Published: (2024-06-01)

Effect of cytochrome P450 3A5 polymorphism on the pharmacokinetics of tacrolimus in renal transplant recipients
by: Yi Yi Htun, et al.
Published: (2020-03-01)

Genome-Wide Association Study of Tacrolimus Pharmacokinetics Identifies Novel Single Nucleotide Polymorphisms in the Convalescence and Stabilization Periods of Post-transplant Liver Function
by: Yuan Liu, et al.
Published: (2019-05-01)

Tacrolimus as Antifungal Agent
by: Lyudmyla Antypenko, et al.
Published: (2019-12-01)

Effects of <i>CYP3A5</i> Genotypes on Thrombocytopenia in Liver Transplantation Patients Treated with Tacrolimus
by: Zhe Guo, et al.
Published: (2023-11-01)

Impact of donor CYP3A5 genotype on pharmacokinetics of tacrolimus in South African paediatric liver transplant patients
by: C Wheeler, et al.
Published: (2024-04-01)

Association of Metabolic Genotype Composite CYP3A5*3 and CYP3A4*1B to Tacrolimus Pharmacokinetics in Stable Black and White Kidney Transplant Recipients
by: Daniel Brazeau, et al.
Published: (2025-10-01)

Individualized tacrolimus therapy: Insights from CYP3A5 polymorphisms and intestinal metabolism
by: Mizuki Mishima, et al.
Published: (2024-09-01)

Effect of CYP3A5 genotypes on pharmacokinetic of tacrolimus in colombian liver transplant patients
by: Erica Fernanda Lindarte, et al.
Published: (2025-03-01)

Pharmacogenetic and Clinical Predictors of Clopidogrel Insufficiency in a Patient with Atherosclerosis Obliterans of the Lower Extremities: Clinical Case
by: M. A. Andreyanova, et al.
Published: (2018-11-01)

CYP3A5 Genotype-Dependent Drug-Drug Interaction Between Tacrolimus and Nifedipine in Chinese Renal Transplant Patients
by: Yilei Yang, et al.
Published: (2021-07-01)